Please use this identifier to cite or link to this item:
|Title:||Current and novel P2Y12 ADP receptor antagonists and bleeding risk in dental surgery|
|Citation:||Mahidol Dental Journal 2016;36(1):65-74.|
|Abstract:||Adenosine diphosphate (ADP) receptor antagonists are anti-platelet drugs used for treatment and prevention of thromboembolism. Clopidogrel, a second generation P2Y12 ADP receptor antagonist, has been used over past decade with or without aspirin in acute coronary syndrome (ACS). Clopidogrel has several drawbacks due to two-step bioactivation by cytochrome P450 (CYP) leading to delayed onset and inter-individual variation. These lead to development of newer ADP receptor antagonists with more predictable pharmacokinetics and pharmacodynamics. The newly approved ADP receptor antagonists include oral prasugrel and ticagrelor, and intravenous cangrelor. During tooth extraction, significant bleeding may occur in patients receiving anti-platelet drugs especially aspirin plus ADP receptor antagonist therapy. This article describes the pharmacological properties and risk of bleeding especially in dental surgery of newly approved ADP receptor antagonists.|
|Appears in Collections:||Pharmacology: National Journal Publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.